MerryLife, Biomedical

MerryLife Biomedical Reports Positive Phase 1 Results and Plans for Global Phase 2 Trial for TML-6, an Oral Multi-Targeted Investigational Therapy for Alzheimer's Disease

Veröffentlicht: 17.03.2026 um 20:44 Uhr, prnewswire.co.uk

Merry Life Biomedical Company, Ltd. Taiwan New York

View original content:https://www.prnewswire.co.uk/news-releases/merrylife-biomedical-reports-positive-phase-1-results-and-plans-for-global-phase-2-trial-for-tml-6-an-oral-multi-targeted-investigational-therapy-for-alzheimers-disease-302659108.html

en | boerse | 68738329 |